European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading

MT Newswires Live09-08 23:28

European equities traded in the US as American depositary receipts were tracking lower late Tuesday morning, declining 0.46% to 1,968.02 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biotech firm Evaxion (EVAX) and telecommunications company Nokia (NOK), which rose 2.6% and 6.5% respectively. They were followed by petroleum refiner Equinor (EQNR) and oil and gas company Eni (E), which were up 2.3% and 2.2% respectively.

The decliners from continental Europe were led by biotech firm BioNTech (BNTX) and internet browser company Opera (OPRA), which fell 4.9% and 2% respectively. They were followed by biopharmaceutical companies argenx (ARGX) and Cellectis (CLLS), which were down 2.2% and 0.3%, respectively.

The gainers from the UK were led by biopharmaceutical company Akari Therapeutics (AKTX) and oil and gas company BP (BP), which increased 2% and 2.5% respectively. They were followed by mining company BHP Group (BHP) and oil and gas company Shell (SHEL), which advanced 3.4% and 2.5% respectively.

The decliners from the UK and Ireland were led by software firm Endava (DAVA), which lost 6.2%. It was followed by biotech firm Autolus Therapeutics (AUTL) and pharmaceutical company Silence Therapeutics (SLN), which dropped 3.6% and 3.4% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment